Abstract
ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of ETV6 have been reported in a variety of epithelial, mesenchymal, and hematological malignancies. In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for (mammary analog) secretory carcinoma, and has not been documented in any other salivary tumor type. The present study comprised a clinical, histologic, and molecular analysis of 10 cases of secretory carcinoma, with typical morphology and immunoprofile harboring a novel ETV6-RET translocation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics*
-
ETS Translocation Variant 6 Protein
-
Female
-
Gene Expression Profiling / methods*
-
Gene Fusion*
-
Genetic Predisposition to Disease
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Immunohistochemistry
-
In Situ Hybridization, Fluorescence
-
Male
-
Mammary Analogue Secretory Carcinoma / chemistry
-
Mammary Analogue Secretory Carcinoma / genetics*
-
Mammary Analogue Secretory Carcinoma / pathology
-
Middle Aged
-
Phenotype
-
Predictive Value of Tests
-
Proto-Oncogene Proteins c-ets / genetics*
-
Proto-Oncogene Proteins c-ret / genetics*
-
Registries
-
Repressor Proteins / genetics*
-
Salivary Gland Neoplasms / chemistry
-
Salivary Gland Neoplasms / genetics*
-
Salivary Gland Neoplasms / pathology
-
Transcriptome
-
Translocation, Genetic*
Substances
-
Biomarkers, Tumor
-
Proto-Oncogene Proteins c-ets
-
Repressor Proteins
-
Proto-Oncogene Proteins c-ret
-
RET protein, human